Education
About Us
Working with TipRanks
Follow Us
MacroGenics Inc (MGNX)
:MGNX
MGNX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.99 - $5.10
Previous CloseN/A
Volume157.79K
Average Volume (3M)631.35K
Market Cap
$114.40M
Enterprise Value$7.42M
Total Cash (Recent Filing)$154.14M
Total Debt (Recent Filing)$37.47M
Price to Earnings (P/E)―
Beta2.11
Next Earnings
Nov 11, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.57
Shares Outstanding63,205,704
10 Day Avg. Volume618,953
30 Day Avg. Volume631,352
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.06
Enterprise Value/Revenue0.05
Enterprise Value/Gross Profit0.05
Enterprise Value/Ebitda-0.16
Forecast
1Y Price Target
$3.50Price Target Upside93.37% Upside
Rating ConsensusHold
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Financial PerformanceMGNX received a $70M upfront cash payment from a royalty purchase agreement for ZYNYZ.
LeadershipMGNX announced the appointment of Eric Risser as President and CEO, signaling potential positive leadership changes.
Product DevelopmentMGNX's second B7-H3 ADC program, MGC026, has the potential to improve upon Vobra Duo and address a broad range of B7-H3-expressing tumors.
Bears Say
Clinical RisksRisks include clinical setbacks with MGC026, lorigerlimab, MGC028, and MGC030, competitive landscape risks, partnership risks, and possible long-term dilution risk.
Financial ForecastMacroGenics reported a full-year 2024 net loss of $1.07 per share, slightly wider than the previous forecast of a net loss of $0.95 per share.
Stock ValuationThe 12-month price target has been lowered to $2 per share from the prior $4 per share.
MacroGenics News
MGNX FAQ
What was MacroGenics Inc’s price range in the past 12 months?
MacroGenics Inc lowest stock price was $0.99 and its highest was $5.10 in the past 12 months.
What is MacroGenics Inc’s market cap?
MacroGenics Inc’s market cap is $114.40M.
When is MacroGenics Inc’s upcoming earnings report date?
MacroGenics Inc’s upcoming earnings report date is Nov 11, 2025 which is in 75 days.
How were MacroGenics Inc’s earnings last quarter?
MacroGenics Inc released its earnings results on Aug 14, 2025. The company reported -$0.57 earnings per share for the quarter, missing the consensus estimate of -$0.423 by -$0.147.
Is MacroGenics Inc overvalued?
According to Wall Street analysts MacroGenics Inc’s price is currently Undervalued.
Does MacroGenics Inc pay dividends?
MacroGenics Inc does not currently pay dividends.
What is MacroGenics Inc’s EPS estimate?
MacroGenics Inc’s EPS estimate is -0.41.
How many shares outstanding does MacroGenics Inc have?
MacroGenics Inc has 63,205,704 shares outstanding.
What happened to MacroGenics Inc’s price movement after its last earnings report?
MacroGenics Inc reported an EPS of -$0.57 in its last earnings report, missing expectations of -$0.423. Following the earnings report the stock price went down -2.469%.
Which hedge fund is a major shareholder of MacroGenics Inc?
Currently, no hedge funds are holding shares in MGNX
MacroGenics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$3.50 (93.37% Upside)
$3.50 (93.37% Upside)
Blogger Sentiment
Neutral
MGNX Sentiment 50%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $150.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 14.5%
Last 30 Days ▲ 14.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-49.15%
12-Months-Change
Fundamentals
Return on Equity
-69.71%
Trailing 12-Months
Asset Growth
22.01%
Trailing 12-Months
Company Description
MacroGenics Inc
MacroGenics, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative monoclonal antibodies for the treatment of cancer and autoimmune diseases. The company specializes in leveraging its proprietary technology platforms, including antibody-drug conjugates and bispecific antibodies, to create targeted therapies that improve patient outcomes. MacroGenics aims to address significant unmet medical needs through its extensive pipeline of product candidates, which are designed to enhance the efficacy and safety profiles of existing treatments.
MGNX Stock 12 Month Forecast
Average Price Target
$3.50
▲(93.37% Upside)
Technical Analysis
Vaxart
―
Pliant Therapeutics
―
Elicio Therapeutics
―
Caribou Biosciences
―
Tenaya Therapeutics
―
Ownership Overview
11.22% Insiders
17.16% Mutual Funds
43.36% Other Institutional Investors
21.64% Public Companies and
Individual Investors